SMAC-armed oncolytic virotherapy enhances the anticancer activity of PD1 blockade by modulating PANoptosis
Our findings demonstrate that the combination of VSV-S and PD1 blockade offers a synergistic therapeutic strategy for HNSCC, supporting the advancement of VSV-based virotherapy as a promising strategy to improve outcomes for HNSCC patients.
Authors
- Jianqiang Yang (ORCID: https://orcid.org/0000-0002-3785-8778)
- Fan Yang (ORCID: https://orcid.org/0000-0002-2993-1023)
- Nabil F. Saba (ORCID: https://orcid.org/0000-0003-4972-1477)
- Liwei Lang (ORCID: https://orcid.org/0000-0002-2374-645X)
- Zhenzhen Fu (ORCID: https://orcid.org/0000-0002-1653-2226)
- Ming Luo (ORCID: https://orcid.org/0000-0003-1766-3487)
- Yong Teng (ORCID: https://orcid.org/0000-0002-1856-7289)
- Sijia Tang (ORCID: https://orcid.org/0009-0007-1357-2218)
- Fanghui Chen (ORCID: https://orcid.org/0009-0007-5382-4352)
Institutions
- Georgia Institute of Technology (US)
- Emory University (US)
- Georgia State University (US)
- Augusta University (US)
- The Wallace H. Coulter Department of Biomedical Engineering (US)
Publication Details
- Journal
- Biomarker Research
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1186/s40364-025-00726-w
- Citations
- 15
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 27.26
Funders
- Emory University
- Augusta University
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health
- Winship Cancer Institute
- National Cancer Institute
- National Institute of Dental and Craniofacial Research